AstraZeneca : Overall survival in TROPION Lung01 fairly inconclusive
>Marginally better than docetaxel - Yesterday evening, AstraZeneca presented new data for its renowned TROPION-Lung01 study, evaluating Dato-DXd versus chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) and having already received at least one line of previous treatment.For the study population as a whole, the results for overall survival were in favour of Dato’ versus docetaxel (12.9 months vs 11.8 months), a...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.